Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary

British Journal of Cancer

Volumn 98, Issue 8, 2008, Pages 1425-1430

  Bridgewater, J ^a   Van Laar, R ^b   Floore, A ^b   Van't Veer, L ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Carcinoma of unknown primary; CUP; Diagnosis; Gene expression profiling; Microarray; Tumour classification

Indexed keywords

CARBOPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE; OXALIPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BLADDER CANCER; BREAST ADENOCARCINOMA; BREAST SURGERY; CANCER OF UNKNOWN PRIMARY SITE; CLINICAL ARTICLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; LARGE INTESTINE CANCER; LUNG SMALL CELL CANCER; MALE; MESOTHELIOMA; MICROARRAY ANALYSIS; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; STOMACH CARCINOMA; TUMOR CLASSIFICATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS;

EID: 42149135334     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604315     Document Type: Article

References (28)

1. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN (1995) Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 13: 2094-2103
2. Bloom G, Yang IV, Boulware D, Kwong KY, Coppola D, Eschrich S, Quackenbush J, Yeatman TJ (2004) Multi-platform, multi-site, micro-array-based human tumor classification. Am J Pathol 164: 9-16
3. Briasoulis E, Tolis C, Bergh J, Pavlidis N (2005) ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol 16(Suppl 1): i75-i76
4. Brown RW, Campagna LB, Dunn JK, Cagle PT (1997) Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol 107: 12-19
5. Buckhaults P, Zhang Z, Chen YC, Wang TL, St Croix B, Saha S, Bardelli A, Morin PJ, Polyak K, Hruban RH, Velculescu VE, Shih Ie M (2003) Identifying tumor origin using a gene expression-based classification map. Cancer Res 63: 4144-4149
6. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413
7. Coleman MP, Rachet B, Woods LM, Mitry E, Riga M, Cooper N, Quinn MJ, Brenner H, Esteve J (2004) Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. Br J Cancer 90: 1367-1373
8. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA (2005) Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 11: 3766-3772
9. Dennis JL, Vass JK, Wit EC, Keith WN, Oien KA (2002) Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin. Cancer Res 62: 5999-6005
10. DeYoung BR, Wick MR (2000) Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Semin Diagn Pathol 17: 184-193
11. Giordano TJ, Shedden KA, Schwartz DR, Kuick R, Taylor JM, Lee N, Misek DE, Greenson JK, Kardia SL, Beer DG, Rennert G, Cho KR, Gruber SB, Fearon ER, Hanash S (2001) Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol 159: 1231-1238
12. Hainsworth JD, Wright EP, Johnson DH, Davis BW, Greco FA (1991) Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining. J Clin Oncol 9: 1931-1938
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
14. Jerusalem G, Hustinx R, Beguin Y, Fillet G (2003) PET scan imaging in oncology. Eur J Cancer 39: 1525-1534
15. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, Berthold F, Schwab M, Antonescu CR, Peterson C, Meltzer PS (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7: 673-679
16. Kuruvilla FG, Park PJ, Schreiber SL (2002) Vector algebra in the analysis of genome-wide expression data. Genome Biol 3: RESEARCH0011
17. Ma XJ, Patel R, Wang X, Salunga R, Murage J, Desai R, Tuggle JT, Wang W, Chu S, Stecker K, Raja R, Robin H, Moore M, Baunoch D, Sgroi D, Erlander M (2006) Molecular Classification of Human Cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 130: 465-473
18. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39: 1990-2005
19. Raber MN, Abbruzzese JL, Frost P (1992) Unknown primary tumors. Curr Opin Oncol 4: 3-9
20. Rades D, Kuhnel G, Wildfang I, Borner AR, Schmoll HJ, Knapp W (2001) Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 12: 1605-1609
21. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP, Poggio T, Gerald W, Loda M, Lander ES, Golub TR (2001) Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA 98: 15149-15154
22. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24: 2786-2792
23. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24: 227-235
24. Schapira DV, Jarrett AR (1995) The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med 155: 2050-2054
25. Shedden KA, Taylor JM, Giordano TJ, Kuick R, Misek DE, Rennert G, Schwartz DR, Gruber SB, Logsdon C, Simeone D, Kardia SL, Greenson JK, Cho KR, Beer DG, Fearon ER, Hanash S (2003) Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Am J Pathol 163: 1985-1995
26. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, Schultz PG, Powell SM, Moskaluk CA, Frierson Jr HF, Hampton GM (2001) Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 61: 7388-7393
27. Tothill RW, Kowalczyk A, Rischin D, Bousioutas A, Haviv I, van Laar RK, Waring PM, Zalcberg J, Ward R, Biankin AV, Sutherland RL, Henshall SM, Fong K, Pollack JR, Bowtell DD, Holloway AJ (2005) An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 65: 4031-4040
28. Varadhachary GR, Abbruzzese JL, Lenzi R (2004) Diagnostic strategies for unknown primary cancer. Cancer 100: 1776-1785